Rayzebio, Inc.
Clinical trials sponsored by Rayzebio, Inc., explained in plain language.
Biotech developing radiopharmaceutical therapies for cancer.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New imaging tracer could spot hidden cancers
Diagnosis Not yet recruitingThis early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…
Phase: EARLY_PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New scan could reveal hidden kidney cancer
Diagnosis Not yet recruitingThis early-phase study tests a new imaging agent called RYZ512 in 10 people with advanced clear cell kidney cancer that has spread. The agent is designed to attach to a protein (CAIX) found on these cancer cells, making them show up on scans. The goal is to see if it is safe and …
Phase: EARLY_PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC